Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb

By Keith Speights - Feb 16, 2018 at 6:08AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a tougher question than simply picking between Cabometyx and Opdivo.

Relatively small up-and-comer or big, established winner? That's basically the choice investors have when it comes to choosing between Exelixis (EXEL 0.34%) and Bristol-Myers Squibb (BMY -0.48%). While the two drugmakers are very different, they also share several things in common. For example, both companies market cancer drugs that are major success stories, and both stocks have performed quite well over the last 12 months.

But which of these two pharma stocks is the better pick for long-term investors? Here are the best arguments for both Exelixis and Bristol-Myers Squibb.

Boxing glove coming out of pill to punch cancer cell

Image source: Getty Images.

The case for Exelixis

Cabometyx. In a word, that's the best reason to buy Exelixis stock. Sales are soaring for the cancer drug. Exelixis won FDA approval in 2016 for Cabometyx as a second-line treatment for renal cell carcinoma, the most common form of kidney cancer. In December 2017, the drug gained FDA approval as a first-line treatment for the disease.

This second approval should be enormously important for Exelixis. The first-line kidney cancer market has nearly as many patients than the second-line and third-line indications combined. Exelixis could have another approval on the way soon: The company plans to submit for approval of Cabometyx in treating liver cancer before the end of March.

There are also opportunities for combinations featuring Cabometyx. One such combination could be with Bristol-Myers Squibb's Opdivo. Exelixis and BMS are evaluating combos of Cabometyx with Opdivo and/or Yervoy as a first-line treatment of kidney cancer. With both monotherapy and combination possibilities, some analysts project that Cabometyx could eventually generate peak annual sales in the U.S. of $2 billion. 

But Cabometyx isn't the only reason to buy Exelixis stock. The company's MEK inhibitor Cotellic could also become a big winner. Cotellic won approval in 2015 in combination with Roche's (NASDAQOTH: RHHBY) Zelboraf for treating advanced melanoma. Sales haven't been anything to get excited over so far. However, there could be a better chance for success with another of Roche's drugs. Roche has several late-stage clinical studies in progress evaluating a combination of Tecentriq with Cotellic in treating melanoma and colorectal cancer. 

Cabometyx by itself should provide great earnings growth for Exelixis over the next few years. Good news from Roche's studies of the Tecentriq/Cotellic combo could add to that growth. And now that Exelixis is profitable, it will likely invest in its pipeline by either licensing or acquiring additional assets. The bottom line is that Exelixis should remain a strong growth stock into the future.

The case for Bristol-Myers Squibb

There isn't a one-word case to be made for buying Bristol-Myers Squibb stock. It takes at least four words -- Opdivo, Eliquis, and cash flow.

Opdivo made nearly $5 billion last year, up 31% from 2016. Market research firm EvaluatePharma projects that it will be the No. 2 best-selling cancer drug in the world by 2022, with sales approaching $10 billion. The main way that sales for Opdivo could double in five years is through combinations with other drugs.

It doesn't hurt that Opdivo is joined in BMS's lineup by a couple of other blockbuster cancer drugs. Leukemia drug Sprycel raked in over $2 billion last year, a 10% year-over-year increase. Sales for Yervoy jumped 18% to $1.2 billion.

The pharma company's product with the best sales growth, though, is Eliquis. The anticoagulant, which BMS co-markets with Pfizer, achieved an impressive 46% year-over-year gain in 2017, with sales of nearly $4.9 billion.

Success for Opdivo, Eliquis, and Bristol-Myers Squibb's other top drugs enable the company to generate solid cash flow. Investors should like what BMS is doing with that cash flow. It pays a nice dividend with a current yield of 2.51%. The company is also looking to use its financial flexibility to make smart strategic deals, most recently buying a stake in and partnering with Nektar Therapeutics.

Better buy

Bristol-Myers Squibb has more arrows in its quiver than Exelixis does. The stock also looks less expensive, with a forward earnings multiple half as large as Exelixis'. And there's the solid dividend that BMS offers, whereas Exelixis doesn't pay a dividend.

So, is Bristol-Myers Squibb the better buy? I like the stock in general, but the company also has a few challenges. Sales for BMS's older drugs, including its hepatitis C franchise, are sinking. As a result, BMS projects revenue growth for 2018 only in the low- to mid-single-digit percentages.

Exelixis, on the other hand, doesn't have much baggage to speak of. While the stock does trade at nearly 38 times expected earnings, factoring in Exelixis' strong growth prospects makes the valuation look much more attractive. 

Bristol-Myers Squibb is definitely the better pick for income investors. But if you're looking for growth, I'd go with Exelixis.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$20.86 (0.34%) $0.07
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$77.37 (-0.48%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.